Photo via Globe Newswire
Insight Molecular Diagnostics Inc., a Nasdaq-listed company headquartered in Nashville, will convene medical professionals on August 17, 2026, to examine advances in transplant monitoring technology. The virtual event will feature discussions led by company executives and external medical experts on how in-house testing can improve outcomes for heart transplant recipients.
The company's GraftAssure platform employs digital PCR technology to measure donor-derived cell-free DNA (dd-cfDNA), a biomarker that helps clinicians detect early signs of organ rejection. According to the announcement, this approach enables transplant centers to conduct sophisticated testing without relying solely on external laboratory partners, potentially reducing turnaround times and improving care coordination.
For Nashville's healthcare sector, the development represents growth in precision diagnostics—an area where the region's medical institutions and biotech companies are increasingly competitive. As transplant volumes rise nationally, tools that streamline rejection monitoring could benefit local hospitals and their transplant programs while positioning Nashville-based iMDx as an innovator in organ preservation and patient monitoring.
